Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe



    Diamyd Medical AB (http://www.omxgroup.com, OMX: DIAM B;
http://www.otcqx.com, OTC: DMYDY)

    STOCKHOLM, Sweden, March 19 /CNW/ - Diamyd Medical (OMX: DIAM B)(OTC:
DMYDY) announced today that the Swedish Medical Products Agency (MPA) has
approved the Company's application to commence Phase III studies with the
therapeutic diabetes vaccine Diamyd(R).

    (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194)

    "I am extremely glad that we now can offer our recently diagnosed type 1
diabetes patients the possibility to participate also in the European study,"
says Professor Johnny Ludvigsson, Linkoping, Sweden, Principal Investigator
for the study.
    Diabetes teams from approximately 20 Swedish pediatric clinics will meet
in Linkoping, Sweden on April 4 to go through details for the study, which
will comprise 306 new onset type 1 diabetes patients. Diamyd Medical is
planning to file clinical trial applications in another 3-4 European countries
and include additionally 20 clinics in the study.
    "The approval from the Swedish MPA is another important step in the
development of Diamyd(R) towards the market," says Elisabeth Lindner,
President and CEO of Diamyd Medical. "Last week we received authorization from
the FDA to start a parallel Phase III trial in the US, and together with
TrialNet's planned study in the US, the interest in Diamyd is strong. We
receive daily inquiries from parents of patients wanting to participate in our
studies."

    http://www.diamyd.com

    Disclaimer: This document contains certain statements relating to the
progress, timing and completion of our research, development and clinical
trials. These statements can be affected by inaccurate assumptions or by known
or unknown risks and uncertainties. Diamyd Medical undertakes no obligation to
publicly update such statements, whether because of new information, future
events or otherwise, nor does Diamyd Medical give any guarantees that the
statements, given or implied, are correct. This document is a translation from
the Swedish original. No guarantees are made that the translation is free from
errors.

    Photo: http://www.newscom.com/cgi-bin/prnh/20080314/297194

    Source: Diamyd Medical AB (publ)





For further information:

For further information: Stockholm office: Elisabeth Lindner, CEO and
President, +46-8-661-0026, elisabeth.lindner@diamyd.com, Chairman; Stockholm
office: Anders Essen-Mvller, +46-8-661-0026, anders.essen-moller@diamyd.com;
Diamyd Medical AB (publ), Linnégatan 89 B, SE-115 23, Stockholm, Sweden

Organization Profile

DIAMYD MEDICAL AB (PUBL)

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890